Exhibits
10-K
from 10-K
136 pages
10-K
02/27/25
EX-10.8
from 10-K
3 pages
Portions of This Exhibit Have Been Redacted Because They Are Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. Amendment One to the Collaboration Agreement
02/27/25
EX-10.9
from 10-K
3 pages
Portions of This Exhibit Have Been Redacted Because They Are Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. Amendment 2 to the Collaboration Agreement
02/27/25
EX-10.34
from 10-K
3 pages
Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Cullinan Therapeutics, Inc. if Publicly Disclosed. Massachusetts Institute of Technology and Cullinan Amber Corp. Third Amendment
02/27/25
EX-19.1
from 10-K
10 pages
Report furnished to security holders
02/27/25
EX-21.1
from 10-K
2 pages
Subsidiaries of the registrant
02/27/25
EX-23.1
from 10-K
2 pages
Consent of expert or counsel
02/27/25
EX-31.1
from 10-K
2 pages
Management certification of annual or quarterly disclosure
02/27/25
EX-31.2
from 10-K
2 pages
Management certification of annual or quarterly disclosure
02/27/25
EX-32.1
from 10-K
2 pages
Management certification of financial report
02/27/25
